Effect of rosuvastatin on fasting and postprandial endothelial biomarker levels and microvascular reactivity in patients with type 2 diabetes and dyslipidemia: a preliminary report.

Kyoung Min KimKyong Yeun JungHan Mi YunSeo Young LeeTae Jung OhHak Chul JangSoo Lim

Published in: Cardiovascular diabetology (2017)

Rosuvastatin treatment for 12 weeks improved microvascular reactivity with concomitant beneficial changes in the postprandial levels of PON-1 and ADMA. These results suggest that rosuvastatin improves the postprandial cardiometabolic milieu in type 2 diabetes. Trial registration ClinicalTrials.gov: NCT02185963 (July 7, 2014).

Keyphrases

blood glucose
type diabetes
glycemic control
insulin resistance
clinical trial
endothelial cells
blood pressure
cardiovascular disease
study protocol
phase iii
metabolic syndrome
open label
gestational age
replacement therapy
smoking cessation